Retatrutide and trizepatide constitute a recent class of medications that target both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. These multifunctional receptor https://tessjgmn803240.blogdun.com/39407662/recent-glp-1-and-gip-receptor-agonists-retatrutide-and-trizepatide